PF-06767832   Click here for help

GtoPdb Ligand ID: 9228

Synonyms: PF06767832
Compound class: Synthetic organic
Comment: PF-06767832 (compound 38) is an orally bioavailable, positive allosteric modulator (PAM) selective for the M1 muscarinic acetylcholine receptor (CHRM1) [2]. It is one of the compounds claimed in patent WO2016009297 [1]. M1 receptor PAMs are being designed for their potential to provide novel therapies for the treatment of M1-mediated diseases and disorders such as Alzheimer's disease.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 112.58
Molecular weight 409.15
XLogP 3.05
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC1COCCC1NC(=O)c1ncc(c(c1)Cc1ccc(cc1)c1cscn1)C
Isomeric SMILES O[C@H]1COCC[C@@H]1NC(=O)c1ncc(c(c1)Cc1ccc(cc1)c1cscn1)C
InChI InChI=1S/C22H23N3O3S/c1-14-10-23-19(22(27)25-18-6-7-28-11-21(18)26)9-17(14)8-15-2-4-16(5-3-15)20-12-29-13-24-20/h2-5,9-10,12-13,18,21,26H,6-8,11H2,1H3,(H,25,27)/t18-,21-/m0/s1
InChI Key VVZZHFMLRHJXTO-RXVVDRJESA-N
References
1. Brodney MA, Davoren JE, Garnsey MR, Zhang L, O'neil SV. (2016)
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators.
Patent number: WO2016009297. Assignee: Pfizer Inc.. Priority date: 18/07/2014. Publication date: 21/01/2016.
2. Davoren JE, Lee CW, Garnsey M, Brodney MA, Cordes J, Dlugolenski K, Edgerton JR, Harris AR, Helal CJ, Jenkinson S et al.. (2016)
Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects.
J Med Chem, 59 (13): 6313-28. [PMID:27275946]
3. Fisher A. (2000)
Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Jpn J Pharmacol, 84 (2): 101-12. [PMID:11128032]